| アブストラクト | Introdution: Immune checkpoint inhibitors (ICIs) have significantly improved clinical outcomes for a wide range of cancers but can also lead to serious or fatal immune-related adverse events (irAEs). Although ICI-related pericardial toxicities have been reported, the clinical features are not well characterized in real-world studies. Objective: To characterize the main features of ICI-related pericardial toxicities and identify factors associated with death. Methods: Data from January 1, 2011 to March 31, 2020 in the FDA Adverse Event Reporting System database were retrieved for disproportionality analysis. We used the reporting odds ratio and the information component (IC) to evaluate the association between ICIs and pericardial adverse events. Clinical characteristics of patients with ICI-associated pericardial toxicities were collected and compared between fatal and non-fatal groups. The time to onset following different ICI regimens was further investigated. Results: We identified a total of 705 ICI-associated pericardial toxicities which appeared to influence more men (53.90%) than women (36.03%), with a median age of 63 (interquartile range [IQR] 54-69) years. Patients with lung cancer accounted for the largest proportion (55.6%). ICI therapies were detected with pharmacovigilance signals of pericardial toxicities, corresponding to IC025 = 2.11 and ROR 4.87 [4.51-5.25]. Nevertheless, there was a lack of association between anti-CTLA-4 and pericardial toxicities. There was no difference in onset time among all ICI regimens. However, TTO of fatal cases (25 days (interquartile range [IQR] 6-70)) occurred statistically earlier than non-fatal cases (42 days (IQR 12-114), p = 0.003). Conclusion: ICI monotherapy (PD-1/PD-L1 therapy) and combination therapy can lead to pericardial toxicities that can result in serious outcomes and tend to occur early. Early recognition and management of ICI-related pericardial disorders should attract clinical attention. The findings require further clinical surveillance for the quantification. |
|---|
| 投稿日 | 2021/7/20 |
|---|
| 投稿者 | Ma, Zhuo; Pei, Jie; Sun, Ximu; Liu, Lihong; Lu, Wenchao; Guo, Qixiang; Lyu, Jiayou; Liu, Yuwei; Zhang, Yuhui; Zhao, Zhixia |
|---|
| ジャーナル名 | Frontiers in pharmacology |
|---|
| 組織名 | Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University,;Beijing, China.;Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital;Medical University, Beijing, China.;A.I. Phoenix Technology Co., Ltd., Hong Kong, China.;Department of Respiratory and Critical Care Medicine, Beijing Institute of;Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34276364/ |
|---|
